Cargando…

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities, and increased mortality. In the last few decades, the management of RA has been dramatically improved by the introduction of a treat-to-target app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biggioggero, Martina, Becciolini, Andrea, Crotti, Chiara, Agape, Elena, Favalli, Ennio Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821397/ https://www.ncbi.nlm.nih.gov/pubmed/31692920 http://dx.doi.org/10.7573/dic.212595

Ejemplares similares

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Structural integrity versus radiographic progression in rheumatoid arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2015)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
por: Favalli, Ennio Giulio, et al.
Publicado: (2018)

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
por: Biggioggero, Martina, et al.
Publicado: (2018)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
por: Favalli, Ennio Giulio, et al.
Publicado: (2014)

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
por: Biggioggero, Martina, et al.
Publicado: (2019)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
por: Genovese, Mark, et al.
Publicado: (2018)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
por: Favalli, Ennio Giulio, et al.
Publicado: (2023)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis
por: Iinuma, Shin, et al.
Publicado: (2022)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
por: Sanmartí, Raimon, et al.
Publicado: (2023)

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
por: Parmentier, Julie M., et al.
Publicado: (2018)

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
por: Vanhoutte, Frédéric, et al.
Publicado: (2017)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
por: Tanaka, Yoshiya, et al.
Publicado: (2022)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
por: Favalli, Ennio G.
Publicado: (2020)

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
por: Namour, Florence, et al.
Publicado: (2018)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
por: Kameda, Hideto, et al.
Publicado: (2021)

Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family
por: Taldaev, Amir, et al.
Publicado: (2021)

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
por: Tarrant, Jacqueline M., et al.
Publicado: (2020)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
por: Strand, Vibeke, et al.
Publicado: (2020)

Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
por: Peterfy, Charles G, et al.
Publicado: (2021)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ra4vutoj56tdmc2quvr651msk